TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03504410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613 + High Dose Cytarabine and Mitoxantrone
Description: CPI-613 + High Dose Cytarabine and Mitoxantrone CPI-613: 2000mg/m2, 5 doses once a day, days 1-5 Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Cytarabine and Mitoxantrone
Description: Cytarabine 1gm/m2, 5 doses every 12hrs starting day 3 through day 5 Mitoxantrone 6mg/m2, 3 doses, once a day following the first, third and fifth doses of Cytarabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone, Etoposide and Cytarabine
Description: Mitoxantrone, Etoposide and Cytarabine~Etoposide 80mg/m over 60 minutes as a central line IV infusion; 6 doses Day 1 though 6 Cytarabine 1000mg/m2 over 3 hours as a central line IV infusion: 6 doses, Day 1 through 6 Mitoxantrone 6 mg/m2 over 30 minutes as a central line IV infusion: 6 dose, Day 1 through 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine, Cytarabine, Filgrastim
Description: Fludarabine, Cytarabine and Filgrastim~Fludarabine 30mg/m2/day over 30 minutes as a central line IV infusion; 5 doses Day 1 though 5 Cytarabine 2g/m2 over 4 hours as a central line IV infusion: 4 hours after Fludarabine: 5 doses, Day 1 through 5 Filgrastim 5µg/kg/day by SQ or as per institutional guidelines starting from Day 1 through Day 5
Study: NCT02321254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The RehaARM-Robot
Description: Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation therapy
Description: Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
Study: NCT03784066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab monotherapy (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab + Tremelimumab
Description: All patients will be treated with postoperative radiotherapy (66 Gy in standard fractionation).~In case of positive section margins or extracapsular extension, 3 cycles of cisplatin 100 mg/msq on days 1, 22, and 43 will be added to standard fractionation radiotherapy (66 Gy).~Durvalumab + Tremelimumab combination therapy: Tremelimumab (75 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 3 cycles postoperative, Durvalumab (1500 mg) will be administered via IV infusion day -14 and at the start of radiation therapy, with repeat administration every 4 weeks at fixed dose for a total of 6 cycles postoperative.
Study: NCT03375450

Intervention type: OTHER
Intervention: Standard of Care
Description: Participants will be followed as per local routine primary healthcare practice
Study: NCT01515787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX (chemotherapy)
Description: Oxaliplatin 85 mg/m\^2 IV over 2 hours on day 1, leucovorin 400 mg/m\^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m\^2 bolus over 5-15 minutes then 2400 mg/m\^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX (chemotherapy)
Description: Oxaliplatin 85 mg/m\^2 IV over 2 hours on day 1, leucovorin 400 mg/m\^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m\^2 bolus over 5-15 minutes then 2400 mg/m\^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5 FUCMT (chemoradiation)
Description: 5-fluorouracil 225 mg/m\^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m\^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5 FUCMT (chemoradiation)
Description: 5-fluorouracil 225 mg/m\^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m\^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Description: low anterior resection with total mesorectal excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: low anterior resection with total mesorectal excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging or endorectal ultrasound
Study: NCT01857713

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reza Band UES Assist Device
Description: Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
Study: NCT03404011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol and Glycerol intake
Description: Intake of 1 gram of propylene glycol/Glycerol mix (50:50). Blood sample before, 5 minutes and 20 minutes after intake.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mimicking intake
Description: Mimicking propylene glycol/glycerol intake with the device turns off. Blood sample before, 5 minutes and 20 minutes after intake.
Study: NCT03665402

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: One of the first line anti-tubercolosis drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: One of the first line anti-tubercolosis drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: One of the first line anti-tubercolosis drug
Study: NCT03554915

Intervention type: OTHER
Intervention: Ketamine-based protocol
Description: For profoundly agitated (physically violent) patients, intramuscular ketamine 5 mg/kg will be administered first line. For severely agitated patients, intramuscular ketamine 3 mg/kg will be administered first line.

Intervention type: OTHER
Intervention: Midazolam-based protocol
Description: For profoundly agitated patients, intramuscular midazolam 15 mg will be administered. For severely agitated patients, intramuscular midazolam 5 mg will be administered.
Study: NCT02973737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: 400 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: 400 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 per day on day 1 through 14, every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m2 per day on day 1 through 14, every 21 days.
Study: NCT05930262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCM acupuncture therapy
Description: TCM acupuncture therapy: Zusanli, Quchi, Hegu, Taichong, Feishu and Fenglong were selected as the main acupoints, and the auxiliary acupoints were selected according to the symptoms, including Fengchi, Dazhui, Lieque, Tiantu, Shenshu, Zhongfu, etc.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drug therapy
Description: Antibiotics were selected based on drug sensitivity test results. Patients with body temperature \> 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional drug therapy
Description: Antibiotics were selected based on drug sensitivity test results. Patients with body temperature \> 38.5℃ were treated with physical cooling and antipyretic drugs. In patients whose sputum was thick and difficult to cough up, nebulization and inhalation therapy was given, as well as effective coughing and patting the back to expel phlegm were guided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: Comprehensive training for hemiplegic limbs included a joint range of motion training, bridging exercise, turnover training, balance training, gait training, hand function training and self-care ability training, 40 min/d, 6 times/w.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Comprehensive training for hemiplegic limbs included a joint range of motion training, bridging exercise, turnover training, balance training, gait training, hand function training and self-care ability training, 40 min/d, 6 times/w.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing training
Description: Training was conducted daily in the morning, or after symptom relief in the case of fever or other discomforts, once a day, 30-40 min/time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: Training was conducted daily in the morning, or after symptom relief in the case of fever or other discomforts, once a day, 30-40 min/time.
Study: NCT01763450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab plus chemotherapy
Description: 1. Bevacizumab:~   7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;~2. Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;~3. Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:~Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;
Study: NCT02112370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine with epinephrine injection
Description: 1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
Study: NCT00689949

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: folic acid
Description: 0.4 mg of folic acid per day
Study: NCT04505098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Icosapent ethyl
Description: 2 g by mouth twice daily for at least 6 months
Study: NCT04092127

Intervention type: OTHER
Intervention: Video Record
Description: Video Record of the premature infant face before and during the RetCam screening of retinopathy of prematurity
Study: NCT03937856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm- Mindfulness Meditation smartphone application
Description: Participants will be asked to register and download the Calm application on participants' phones or home computer. Daily use for a minimum of 5 minutes will be suggested and will be recorded at study end.
Study: NCT04538664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered as an IV infusion at a dose of 1400 mg (1750 mg if body weight is \>=80 kilogram \[kg\]) by once weekly up to Cycle 2 Day 1, then 1750 mg (2100 mg if body weight is \>=80 kg) on Day 1 of each 21-day cycle, starting with Cycle 3 and will continue the same treatment in OLE phase then in LTE phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm A and will continue the same treatment in OLE phase then in LTE phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as AUC 5 IV infusion for up to 4 cycles on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered as 500 mg/m\^2 IV infusion (with vitamin supplementation) on Day 1 of each 21-day cycle and then as maintenance monotherapy until disease progression in Arm B and will continue the same treatment in OLE phase then in LTE phase.
Study: NCT01573273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal administration, 40 IUs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal administration, 40 IUs
Study: NCT04082195

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fooya mobile game
Description: An application that incorporates the science and technology of immersive gaming, neuropsychology and cognitive behavior therapy in a mobile health game to target early childhood nutrition literacy and health promotion in a fun and exciting way.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Uno board game
Description: A popular board game which is not a mobile app.
Study: NCT02123485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low frequency (1 hz) rTMS, as add-on to ECT
Description: Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-rTMS
Description: Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
Study: NCT02560610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OC000459

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01843218

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of erectile dysfunction
Description: Register R / P and self-administered questionnaire IIEF-5
Study: NCT03224897

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cathodal tDCS
Description: Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anodal tDCS
Description: 1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: 1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups.
Study: NCT03238820

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic gastric gastrointestinal stromal tumors resection
Description: Robotic gastric gastrointestinal stromal tumors resection
Study: NCT06437873

Intervention type: PROCEDURE
Intervention: Total Thyroidectomy (TT)
Description: TT:Surgical removal of the entire thyroid gland.

Intervention type: RADIATION
Intervention: Radioactive iodine treatment(RAIT)
Description: RAIT:Administration of radioactive iodine to eliminate remaining thyroid tissue or cancer cells.
Study: NCT03961282

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doorway Width Test
Description: The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doorway Width Test
Description: The first test consists of Doorway Width. Standard level is a doorway width of 30 inches; Enhanced is doorway width of 36 inches; Co-design allows the participant to adjust the width anywhere from 26 to 48 inches.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Door Frame Color Test
Description: The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Door Frame Color Test
Description: The second test consists of Door Frame Color. Standard level is same color (hue) as light-color wall; Enhanced level is same hue but of higher color intensity for contrast; Co-design allows the participant to adjust the color intensity range from lowest (same as wall) to highest intensity (stronger contrast than in Enhanced).
Study: NCT03747146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Adductor Canal Catheter (ACC)
Description: At the end of the case or in the PACU, a pseudo sham catheter will be affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Adductor Canal block with sham catheter
Description: Adductor canal block (ACB) will be administered. At the end of the case or in the PACU, a catheter will be inserted and affixed mid-thigh to the skin using dermabond, steri-strips, and a chg tegaderm dressing. The catheter will be connected to the disposable pump filled with sterile saline (400 cc) and the flow rate will be set to 0. The pump will be enclosed in a carrier bag provided by the company. To ensure blinding, the carrier bag will be taped to prevent the patient from accessing it.
Study: NCT04077905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: 35mg/m² ivgtt on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m² ivgtt on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,
Study: NCT03243994

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Absorption test with D-xylose and zink
Description: Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Absorption test with D-xylose and zink
Description: Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
Study: NCT03017560

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized cognitive treatment
Description: Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
Study: NCT00985205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enteral Glutamine
Description: 0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric or feeding tube q4 hrs or TID or QID if po.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin mixed with water given via NG or feeding tube Q 4 hours or TID or QID if po.
Study: NCT00883246

Intervention type: DEVICE
Group type: OTHER
Intervention: SilverHawk & TurboHawk Peripheral Plaque Excision System
Description: Removal of atherosclerotic plaque from artery walls.